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Summary
Background Sub-Saharan Africa and southern Asia account for almost 85% of global maternal deaths from 
post-partum haemorrhage. Early administration of tranexamic acid, within 3 h of giving birth, was shown to reduce 
the risk of death due to bleeding in women with post-partum haemorrhage in the World Maternal Antifibrinolytic 
(WOMAN) trial. We aimed to assess the cost-effectiveness of early administration of tranexamic acid for treatment 
of post-partum haemorrhage.
Methods For this economic evaluation we developed a decision model to assess the cost-effectiveness of the addition 
of tranexamic acid to usual care for treatment of women with post-partum haemorrhage in Nigeria and Pakistan. 
We used data from the WOMAN trial to inform model parameters, supplemented by estimates from the literature. 
We estimated costs (calculated in 2016 US$), life-years, and quality-adjusted life-years (QALYs) with and without 
tranexamic acid, calculated incremental cost-effectiveness ratios (ICERs), and compared these to threshold values in 
each country. Costs were assessed from the health-care provider perspective and discounted at 3% per year in the base 
case analysis. We did a series of one-way sensitivity analyses and probabilistic sensitivity analysis to assess the 
robustness of the results to parameter uncertainty.
Findings Early treatment of post-partum haemorrhage with tranexamic acid generated an average gain of 0·18 QALYs 
at an additional cost of $37·12 per patient in Nigeria and an average gain of 0·08 QALYs at an additional cost of 
$6·55 per patient in Pakistan. The base case ICER results were $208 per QALY in Nigeria and $83 per QALY in 
Pakistan. These ICERs were below the lower bound of the cost-effectiveness threshold range in both countries. The 
ICERs were most sensitive to uncertainty in parameter inputs for the relative risk of death due to bleeding with 
tranexamic acid, the discount rate, the cost of the drug, and the baseline probability of death due to bleeding.
Interpretation Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria 
and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar 
baseline risk of death due to bleeding.
Funding London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and 
Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Between 1990 and 2015, the global maternal mortality 
ratio declined from 385 deaths per 100 000 births to 
216 deaths per 100 000 births but fell short of the 
75% reduction called for in the Millennium Development 
Goals (MDG) framework.1 In 2015, the continued commit­
ment to reducing maternal mortality was outlined in 
the Sustainable Development Goals (SDGs), which estab­
lished a target of reducing the global maternal 
mortality ratio to less than 70 per 100 000 births by 2030.2 
Post­partum haemorrhage, commonly defined as a blood 
loss of more than 500 mL within 24 h of giving birth, 
is a leading cause of maternal death, accounting for 
approximately 20% of maternal deaths globally.3 Inter­
ventions aimed at preventing or treating post­partum 
haemorrhage can have an important role in working 
towards the SDG target.
Tranexamic acid is a drug that reduces bleeding by 
inhibiting the breakdown of fibrin blood clots.4 The effect 
of tranexamic acid in reducing the risk of death from post­
partum haemorrhage was shown in the World Maternal 
Antifibrinolytic (WOMAN) trial, a randomised, double­
blind, placebo­controlled study that enrolled more than 
20 000 women in 21 countries between March, 2010, 
and April, 2016.5 The burden of maternal deaths falls 
disproportionately on low­income and middle­income 
countries; sub­Saharan Africa and southern Asia account 
for almost 85% of global maternal deaths from post­partum 
haemorrhage.3 In resource­constrained settings, the 
decision to adopt a medicine for routine use in clinical 
practice should be informed not only by information about 
the clinical effective ness of an intervention but also by 
information about its cost­effectiveness.6 We aimed to 
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evaluate the cost­effectiveness of tranexamic acid for 
treatment of post­partum haemorrhage in Nigeria and 
Pakistan. Cost­effectiveness analyses at the country level 
are needed to reflect differences in both costs and the 
baseline risk of maternal death. We focus on Nigeria and 
Pakistan because they are among the countries with the 
highest number of maternal deaths annually7 and more 
than 50% of patients in the WOMAN trial were enrolled 
from these two countries.
Methods
Model structure and comparators
For this economic evaluation we developed a decision 
tree (figure 1) to evaluate the cost­effectiveness of treating 
post­partum haemorrhage with and without tranexamic 
acid using data from the WOMAN trial, supplemented 
by literature­based sources where necessary. In the 
model, following diagnosis of post­partum haemorrhage, 
there are three possible outcomes: death due to bleeding, 
death from other causes, or alive at discharge (or 42 days 
after randomisation if not yet discharged).8 Because of its 
mechanism of action, tranexamic acid is not expected to 
have any effect on deaths that are not related to bleeding5 
and therefore these events are estimated separately in the 
model. For patients who were alive at discharge, the 
model assumes that their long­term survival is equivalent 
to the age­adjusted life expectancy of the general female 
population in each country.9,10
In the WOMAN trial, tranexamic acid was admin­
istered by intravenous injection. Results of prespecified 
subgroup analyses showed that the effect of tranexamic 
acid in reducing the risk of death due to bleeding varied 
with time to initiation of treatment. Early treatment, 
defined as administration of tranexamic acid within 3 h 
of giving birth, substantially reduced the risk of death 
due to bleeding compared with placebo (risk ratio 
[RR] 0·69, 95% CI 0·52–0·91) whereas no reduction was 
observed when tranexamic acid was given after 3 h.5 This 
cost­effectiveness model therefore evaluated the effect 
of early treatment with tranexamic acid by focusing on 
the subgroup of patients who received treatment within 
3 h of giving birth in the WOMAN trial.
The cost­effectiveness model was constructed with the 
software package TreeAge Pro 2017. Analyses of data 
Research in context
Evidence before this study
We searched the PubMed database to identify cost-effectiveness 
analyses of tranexamic acid published before June, 2017. Two 
searches were done, with the following search terms: cost 
effectiveness AND tranexamic acid (filter: humans); and cost 
effectiveness AND post-partum haemorrhage (filter: humans). 
Eligible studies had to include a comparative analysis of both 
costs and effectiveness and to report results in terms of an 
incremental cost-effectiveness ratio. We identified three studies 
that had evaluated the cost-effectiveness of tranexamic acid, 
two in bleeding trauma patients and one in patients who had 
elective surgery. We did not identify any previous studies that 
had assessed the cost-effectiveness of tranexamic acid for 
treatment of women with post-partum haemorrhage.
Added value of this study
The international, multicentre, randomised World Maternal 
Antifibrinolytic (WOMAN) trial, which enrolled over 
20 000 patients between March, 2010, and April, 2016, 
showed that early administration of tranexamic acid reduces 
the risk of death due to bleeding in women with post-partum 
haemorrhage. This economic evaluation draws on data from 
the WOMAN trial to inform an assessment of the 
cost-effectiveness of tranexamic acid for treatment of women 
with post-partum haemorrhage in Nigeria and Pakistan, taking 
into account country-specific differences in both costs and 
baseline risk of mortality.
Implications of all the available evidence
Consistent with the results of previous cost-effectiveness 
analyses in other patient groups and settings, the findings 
presented in this study suggest that early administration of 
tranexamic acid in women with post-partum haemorrhage is 
cost-effective. This finding is important given the resource 
constraints faced by countries in sub-Saharan Africa and 
southern Asia, two regions with a disproportionate burden 
of global maternal deaths due to post-partum haemorrhage.
Figure 1: Decision tree
Structure of the decision tree used to evaluate the cost-effectiveness of treating 
post-partum haemorrhage with and without tranexamic acid and showing 
where the effect of tranexamic acid in reducing the relative risk of death due to 
bleeding is applied in the model.
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from the WOMAN trial to inform the cost­effectiveness 
model were done in Stata, version 14.
Study conduct
The WOMAN trial was done in accordance with good 
clinical practice guidelines of the International Conference 
on Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH).11 The consent 
procedures are described in detail in the protocol.8 The 
procedure at each site was approved by the relevant ethics 
committee and regulatory agencies. The trial is registered 
with the ISRCTN registry, number ISRCTN76912190 
(Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; 
and the Pan African Clinical Trials Registry, number 
PACTR201007000192283.
Data inputs
The model reports outcomes in terms of both survival 
(in years) and quality­adjusted life­years (QALYs). 
Survival estimates were informed by data from the 
WOMAN trial. The baseline probability of death due to 
bleeding in each country was estimated from the placebo 
group (table 1), to which the relative risk of death for 
patients who received tranexamic acid was applied. To 
estimate the probability of death from other causes, we 
first used a χ² test to assess the equality of proportions 
between the placebo and tranexamic acid groups and 
found no difference. Therefore, we calculated a single 
estimate of the probability of death from other causes 
that we applied to both groups in the cost­effectiveness 
model. We estimated time to death due to bleeding, time 
to death from other causes, and time to discharge by 
pooling data from both groups of the WOMAN trial after 
t tests confirmed that there were no differences between 
patients who received tranexamic acid and patients who 
received placebo.
A QALY is an outcome measure that combines 
mortality and morbidity into a single index, thereby 
recognising that health improvements can reflect gains 
in both quantity and quality of life.12 To estimate QALYs, 
the time spent in a given health state is multiplied 
by a quality­adjustment weight, also referred to as 
a health­state utility value. The conventional scale 
for health­state utility values ranges from 0 (death) 
to 1 (perfect or full health).12 In the WOMAN trial, health 
status was measured in patients who were alive at 
discharge (or 42 days after randomisation) by the doctor 
or midwife with the proxy version of the European 
Quality of Life 5 Dimensions­3 Level (EQ­5D­3L) 
questionnaire and converted to index scores via the value 
set for the UK (table 2). At present, no value sets are 
available for Nigeria and Pakistan. We observed no 
difference in index scores between patients who received 
tranexamic acid and patients who received placebo, 
and therefore the same value of 0·895 was applied 
to all patients for the period between randomisation 
and discharge.
For patients who were alive at discharge, we assumed a 
health­state utility value for the post­discharge period until 
death of 0·93, based on values for the UK general female 
population.13 For patients who died, a health­state utility 
value of 0·41 was obtained from a published systematic 
review of women undergoing emergency caesarean 
section requiring intensive care and was applied to the 
period between randomisation and death.14
We considered costs from the perspective of the 
health­care provider and included the cost of tranexamic 
acid plus the cost of administration,15,16 and the cost 
of hospital stays (table 3).17 Tranexamic acid was 
administered as a 1 g dose by slow intravenous injection. 
Administration costs in the model took into account the 
cost of syringes and the cost of 10 min of nurse time 
derived from WHO­CHOICE region­specific personnel 
costs.15 As indicated in the protocol, if bleeding 
continued after 30 min or restarted within 24 h of 
the first dose, a second 1 g dose could be given.8 
Approximately 30% of patients received a second dose 
of tranexamic acid. To calculate the cost of hospital 
Base case 
value
Range (one-way 
sensitivity 
analysis)*
Distribution (probabilistic 
sensitivity analysis)
Baseline probability of death due to bleeding
Nigeria 2·79% 2·08–3·65 Beta: r=51; n=1831
Pakistan 1·12% 0·72–1·66 Beta: r=24; n=2141
Relative risk (RR) of death due to bleeding 
with tranexamic acid given within 3 h
0·69 0·52–0·91 Lognormal: ln(RR) –0·370; 
SE[ln(RR)] 0·137
Baseline probability of death from other causes
Nigeria 0·76% 0·50–1·09 Beta: r=28; n=3694
Pakistan 0·67% 0·45–0·97 Beta: r=29; n=4308
Time to death due to bleeding, years 0·0015 0·0007–0·0023 Gamma: mean 0·0015; SE 0·0004
Time to death due to other causes, years 0·0078 0·0051–0·0104 Gamma: mean 0·0078; SE 0·0013
Time to discharge, years 0·0093 0·0092–0·0095 Gamma: mean 0·0093; SE 0·0001
Post-discharge age-adjusted female life expectancy, years†
Nigeria 40·9 36·8–45·7 Normal: mean 40·9; SE 1·28
Pakistan 49·2 45·9–52·2 Normal: mean 49·2; SE 1·02
All data are from the WOMAN trial,5 unless otherwise stated. *For inputs derived from the WOMAN trial, the range 
reflects the 95% CI. †Sources: WHO Global Health Observatory,9 Lopez et al (2000).10
Table 1: Data inputs to estimate survival in the cost-effectiveness model
Base 
case 
value
Range (one-way 
sensitivity 
analysis)*
Distribution (probabilistic 
sensitivity analysis)
Source
Utility value for patients alive at 
discharge
0·895 0·892–0·897 Beta: mean 0·895; SE 0·001 WOMAN trial5
Utility value for patients in 
hospital before death (any cause)
0·41 0·20–0·63 Beta: mean 0·41; SE 0·11 Alfirevic et al 
(2016)14
Utility value after discharge 
(general female population)
0·93 0·91–0·94 Beta: mean 0·93; SE 0·007 Kind et al 
(1999)13
*For inputs derived from the WOMAN trial, the range reflects the 95% CI.
Table 2: Data inputs for health-state utility values in the cost-effectiveness model
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stays, we multiplied the time between randomisation 
and discharge by country­specific estimates of cost per 
hospital bed­day based on WHO­CHOICE health service 
delivery costs, which estimate the hotel component of 
hospital costs, including personnel, capital, and food 
costs but excluding condition­specific treatments and 
diagnostic tests.17
In the model, we also considered the influence of 
clinical events that differed significantly between 
treatment groups and that were expected to incur 
additional costs for the health­care provider. For patients 
in the WOMAN trial who received treatment within 3 h 
of giving birth, no significant differences were observed 
between groups in the rates of brace suture, mechanical 
ventilation, transfusion, hysterectomy, administration 
of uterotonic drugs, or number of days spent in the 
intensive care unit (appendix). However, the rate of 
laparotomy was higher in the placebo group than in the 
tranexamic acid group; therefore, we took the cost of 
laparotomy into account in our analysis.
The model did not attempt to account for future 
health­care costs beyond the time horizon of the trial.18 
Unit cost data that were sourced from the literature were 
converted to 2016 US$ with purchasing power parity.19
Model outputs and sensitivity analyses
The main outputs of the cost­effectiveness model are 
average per­patient costs, life­years, and QALYs for 
treatment of post­partum haemorrhage with and without 
tranexamic acid and calculation of the incremental 
cost­effectiveness ratio (ICER), which is the ratio of 
the difference in costs between treatment strategies 
to the difference in QALYs. The resulting ICER can 
be compared to a country­specific cost­effectiveness 
threshold value; an ICER that falls below the threshold 
value would generally be considered cost­effective. We 
adopted a range of cost­effectiveness threshold values in 
each country ($446–$2880 per QALY in Nigeria and 
$314–$2416 per QALY in Pakistan), which were obtained 
from an analysis by Woods and colleagues.20 Their 
calculation of cost­effectiveness thresholds is based on 
the premise that health­care budgets are constrained; 
if an intervention offers health gains but also 
incurs additional costs, then the decision to fund the 
intervention should be informed by the value of the 
other interventions that must be foregone. The cost­
effectiveness threshold ranges estimated by Woods and 
colleagues are based on an understanding of the 
association between changes in health­care expenditure 
and health outcomes in the National Health Service 
(NHS) in England, which was then applied to other 
countries with different income levels by use of estimates 
of the income elasticity of the value of health.20
To address uncertainty in the data inputs for the 
cost­effectiveness model, we did a series of one­way 
sensitivity analyses varying one parameter at a time and 
observing the effect on the ICER. All parameters listed 
in tables 1–3 were varied across the ranges specified, 
with the exception of the administration cost of 
tranexamic acid. In the base case analysis, a discount 
rate of 3% per year was applied in the model but we 
explored the effect of varying this rate from 1·5% to 
10% in one­way sensitivity analyses.21 The reason for 
discounting in a cost­effectiveness analysis is to reflect 
the fact that costs and health benefits in the present are 
valued more highly than costs and health benefits 
occurring in the future.22
See Online for appendix
Base 
case 
value
Range (one-way 
sensitivity 
analysis)*
Distribution 
(probabilistic 
sensitivity 
analysis)
Sources
Mean number of doses of 
tranexamic acid administered
1·29 1·28–1·30 Gamma: mean 1·29; 
SE 0·005
WOMAN trial5
Cost per 1 g dose of tranexamic acid (US$)
Nigeria 29·84 4·30–34·00 NA Hilton Pharma Ltd
Pakistan 5·60 4·30–10·70 NA Holy Family Hospital 
(Rawalpindi, Pakistan)
Cost of administration per dose of tranexamic acid: two syringes, 10 min nurse time (US$)
Nigeria 1·50 NA NA WHO-CHOICE,15 WHO16
Pakistan 0·59 NA NA WHO-CHOICE,15 WHO16
Cost per hospital bed-day (US$)
Nigeria 24·77 23·74–32·03 NA WHO-CHOICE17
Pakistan 32·15 30·80–41·59 NA WHO-CHOICE17
Proportion of patients requiring 
laparotomy (placebo)
1·08% 0·86–1·34 Beta: r=80; n=7408 WOMAN trial5
Proportion of patients requiring 
laparotomy (tranexamic acid)
0·55% 0·39–0·74 Beta: r=41; n=7475 WOMAN trial5
Cost of laparotomy (US$)
Nigeria 746 154–905 NA University College 
Hospital (Ibadan, 
Nigeria)
Pakistan 330 172–480 NA Holy Family Hospital 
(Rawalpindi, Pakistan)
NA=not applicable. *For inputs derived from the WOMAN trial, the range reflects the 95% CI.
Table 3: Data inputs to estimate costs in the cost-effectiveness model
Cost (US$) Life-years QALYs ICER Cost-effectiveness 
threshold range*
Nigeria
Tranexamic acid 127·18 22·13 20·58 .. ..
No tranexamic acid 90·06 21·94 20·40 .. ..
Difference 37·12 0·19 0·18 $208 per QALY $446–$2880 per QALY
Pakistan
Tranexamic acid 118·03 24·59 22·86 .. ..
No tranexamic acid 111·48 24·50 22·78 .. ..
Difference 6·55 0·09 0·08 $83 per QALY $314–$2416 per QALY
QALY=quality-adjusted life-year. ICER=incremental cost-effectiveness ratio. *Values were adjusted for purchasing 
power parity.20
Table 4: Average costs, life-years, and QALYs per patient with and without tranexamic acid for the 
treatment of post-partum haemorrhage as well as base case ICERs in each country 
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We also explored the combined effect of parameter 
uncertainty on the ICER by simultaneously sampling 
input values across multiple parameters by use 
of probabilistic sensitivity analysis.23 We assigned 
distributions for parameter estimates derived from the 
WOMAN trial and health­state utility values from the 
literature (tables 1 and 2) and used Monte Carlo simulation 
to draw 10 000 samples across all dis tributions. We present 
the results with a cost­effectiveness acceptability curve to 
show the probability that treatment of post­partum 
haemorrhage with tranexamic acid is cost­effective across 
a range of threshold values in each country.20
Role of the funding source
The funders of this study had no role in the study design, 
data collection, data interpretation, data analysis, or 
writing of this report. The authors had full access to all 
the data and had final responsibility for the decision to 
submit for publication.
Results
Average costs, life­years, and QALYs per patient for 
treatment of post­partum haemorrhage with and 
without tranexamic acid in Nigeria and Pakistan are 
summarised in table 4. Although the effect of 
tranexamic acid in reducing the risk of death due to 
bleeding in the model is the same in both countries, 
we observed differences in survival and QALYs because 
the baseline probabilities of death due to bleeding and 
post­discharge life expectancies differ between the two 
countries. Table 4 also summarises the base­case point 
estimates for the ICERs and the country­specific 
threshold ranges. The ICER estimates are below the 
lower bounds of the cost­effectiveness threshold 
ranges, which suggests that treatment of post­partum 
haemorrhage with tranexamic acid is cost­effective in 
both countries.
We did a series of one­way sensitivity analyses to 
explore the effect of varying different parameters 
across a plausible range of values on the ICER. 
Figure 2 shows those parameters that led to a change 
in the ICER of greater than $20 per QALY when inputs 
were varied from the lowest to the highest values over 
the specified ranges. In both countries, the ICER was 
shown to be most sensitive to variations in the relative 
risk of death due to bleeding with tranexamic acid, the 
discount rate, the cost of tranexamic acid, and the 
baseline probability of death due to bleeding. In 
Pakistan, when the relative risk of death due to 
bleeding with tranexamic acid was increased to 0·91, 
the ICER remained below the lower bound of the 
cost­effectiveness threshold of $314 per QALY. In 
Nigeria, increasing the relative risk of death due to 
bleeding with tranexamic acid to the upper bound of 
0·91 resulted in an ICER of $692 per QALY, while 
increasing the discount rate to 10% resulted in an 
ICER of $507 per QALY. These ICERs are still within 
the cost­effectiveness threshold range for Nigeria 
($446–$2880 per QALY). This analysis suggests that the 
cost­effectiveness results are robust to the uncertainty 
surrounding the value of the inputs for the key 
parameters in the model.
Figure 3 shows the effect of simultaneously vary­
ing the value of multiple parameters in the cost­
effectiveness model on the ICER in each country. The 
Figure 2: Tornado diagram showing the effect of varying each parameter on its own on the ICER in Nigeria 
and Pakistan
Only parameters that resulted in a difference of more than $20 per quality-adjusted life-year (QALY) in the 
incremental cost-effectiveness ratio (ICER) when varied between the lower and upper bounds of the plausible 
ranges are shown. The vertical line indicates the base case estimate of the ICER. The cost-effectiveness threshold 
range is $446–$2880 per QALY in Nigeria and $314–$2416 per QALY in Pakistan.
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Figure 3: Cost-effectiveness acceptability curves showing the probability that tranexamic acid is cost-effective 
across a range of threshold values in Nigeria and Pakistan
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vertical axis indicates the probability that tranexamic 
acid is cost­effective at different threshold values on the 
horizontal axis. At the lower end of the threshold range 
for Pakistan ($314 per QALY), the probability that 
tranexamic acid is cost­effective is 98%. At the lower end 
of the threshold range for Nigeria ($446 per QALY), the 
probability that tranexamic acid is cost­effective is 93%.
Discussion
Administration of tranexamic acid to women with 
post­partum haemorrhage has been shown to save lives 
when the drug is given within 3 h of giving birth,5 but 
this intervention incurs additional costs. We sought to 
evaluate whether the additional costs associated with 
routine use of tranexamic acid in women with 
post­partum haemorrhage represent an efficient use of 
scarce resources. We did this analysis in two countries 
with a high burden of maternal mortality, Nigeria and 
Pakistan, and found that tranexamic acid is likely to be 
highly cost­effective in both countries. Although this is 
the first analysis to evaluate the cost­effectiveness 
of tranexamic acid for treatment of post­partum 
haemorrhage, our findings are broadly consistent with 
those of previous economic evaluations that have shown 
the cost­effectiveness of tranexamic acid for treatment of 
excessive blood loss in other patient groups, including 
treatment of patients with bleeding trauma and those 
who have had elective surgery.24–26
As an inexpensive and potentially life­saving inter­
vention, it is perhaps not surprising that tranexamic acid 
has been shown to be cost­effective in different settings, 
although uncertainty surrounding the price of the 
drug has been shown to have a substantial effect on 
ICER estimates in sensitivity analyses in our study and 
in previous studies.24,25 Another important source of 
uncertainty in our cost­effectiveness analysis was the 
baseline probability of death due to bleeding in each 
country. We chose to evaluate the cost­effectiveness of 
tranexamic acid in countries with high maternal 
mortality as this is the setting where we expect to see the 
largest benefit in terms of a reduction in the number of 
deaths due to bleeding. Caution should be exercised in 
generalisation of the cost­effectiveness results reported 
here to countries with much lower baseline rates of 
maternal mortality due to post­partum haemorrhage. It 
is also important to consider the generalisability of the 
results of this analysis across different settings within 
Nigeria and Pakistan, given the realities of health­care 
provision in both countries. We have evaluated the 
cost­effectiveness of tranexamic acid when given within 
3 h of birth, which requires timely access to skilled 
health personnel. According to estimates from 2012, the 
proportion of births attended by skilled health personnel 
was 56% in Pakistan.27 In Nigeria, where there are 
substantial within­country socioeconomic inequalities 
in access to maternal health care, the proportion 
was 40%.27,28
Our cost­effectiveness analysis has a number of 
potential limitations. The maximum period of follow­up 
in the WOMAN trial was 42 days and therefore in the 
cost­effectiveness model it was necessary to make a 
general assumption about long­term survival be yond the 
trial period. We based our assumption on country­
specific average estimates of age­adjusted female life 
expectancy from the literature.9 This assumption meant 
that the time horizon of the model for patients who were 
alive at discharge was quite long, making the results 
sensitive to variations in the discount rate. For this 
reason, we tested the effect of increasing the discount 
rate up to 10% and found that tranexamic acid remained 
cost­effective in one­way sensitivity analysis. Another 
limitation of the short follow­up period is that we were 
unable to collect any data on wider health benefits beyond 
the immediate survival of the mother. For example, we 
did not attempt to measure or quantify the effects of 
maternal survival on the survival or quality of life of 
the newborn child or the family, thereby potentially 
underestimating the benefits of tranexamic acid.
To use the results of any cost­effectiveness analysis to 
inform decision making, it is necessary to compare the 
ICER generated by the model to a threshold value. 
Various different approaches have been used to 
estimate cost­effectiveness thresholds.20 Historically, 
the ICERs for health interventions in low­income and 
middle­income countries have been compared to a 
threshold value of one to three times the country’s 
gross domestic product (GDP) per capita.20,29 This 
approach for estimation of the threshold is conceptually 
linked to how individuals value health and their 
willingness to pay for additional health benefits, but it 
has been criticised because this measure is not directly 
linked to an assessment of the value of a new 
intervention in relation to what other health­generating 
interventions would need to be displaced.20,29,30 In this 
study, we chose to compare the ICER results to 
cost­effectiveness threshold ranges that were estimated 
on the basis of the opportunity costs of health­care 
spending that better reflect the constrained nature of 
health­care budgets. The thresholds we used are lower 
and therefore more stringent than thresholds based 
on GDP per capita. This approach gives us further 
confidence in our conclusion that early administration 
of tranexamic acid is cost­effective for the treatment of 
post­partum haemorrhage in Nigeria and Pakistan.
Contributors
HS and IR were responsible for conceiving, designing and conducting 
the WOMAN trial. BL and AM led the development of the 
cost­effectiveness model. All authors contributed to the conception of 
the cost­effectiveness analysis and the interpretation of results, critically 
revised the paper and approved the final version.
Declaration of interests
We declare no competing interests. 
Acknowledgments
The run­in phase of the WOMAN trial for recruitment of 2000 patients 
was funded by London School of Hygiene & Tropical Medicine 
Articles
www.thelancet.com/lancetgh   Vol 6  February 2018 e228
(London, UK). The funds to support the drug and placebo costs through 
an investigator­initiated research grant for the run­in phase were 
provided by Pfizer. The main phase was funded by the Department of 
Health (UK), grant number HICF­T2­0510­007, and the Wellcome Trust, 
grant number WT094947. The Bill & Melinda Gates Foundation 
(grant number OPP1095618) supported dissemination activities and 
recruitment of the final 5000 patients. We thank Bukola Fawole (Nigeria) 
and Rizwana Chaudhri (Pakistan) for their assistance in providing data 
to inform cost estimates.
References
1 Alkema L, Chou D, Hogan D, et al. Global, regional, and national 
levels and trends in maternal mortality between 1990 and 2015, 
with scenario­based projections to 2030: a systematic analysis by 
the UN Maternal Mortality Estimation Inter­Agency Group. 
Lancet 2016; 387: 462–74.
2 UN. Transforming our world: the 2030 agenda for sustainable 
development. A/RES/70/1. 2015. https://sustainabledevelopment.
un.org/post2015/transformingourworld/publication 
(accessed June 12, 2017).
3 Say L, Chou D, Gemmill A, et al. Global causes of maternal death: 
a WHO systematic analysis. Lancet Glob Health 2014; 2: e323–33.
4 Cesarman­Maus G, Hajjar KA. Molecular mechanisms of 
fibrinolysis. Br J Haematol 2005; 129: 307–21.
5 WOMAN Trial Collaborators. Effect of early tranexamic acid 
administration on mortality, hysterectomy, and other morbidities in 
women with post­partum haemorrhage (WOMAN): an international, 
randomised, double­blind, placebo­controlled trial. Lancet 2017; 
389: 2105–16.
6 WHO. Essential medicines and health products. http://www.who.int/
medicines/services/essmedicines_def/en/ (accessed June 12, 2017).
7 Kassebaum NJ, Bertozzi­Villa A, Coggeshall MS, et al. 
Global, regional, and national levels and causes of maternal 
mortality during 1990–2013: a systematic analysis for the Global 
Burden of Disease Study 2013. Lancet 2014; 384: 980–1004.
8 Shakur H, Elbourne D, Gülmezoglu M, et al. The WOMAN Trial 
(World Maternal Antifibrinolytic Trial): tranexamic acid for the 
treatment of postpartum haemorrhage: an international randomised, 
double blind placebo controlled trial. Trials 2010; 11: 40.
9 WHO Global Health Observatory. Life tables by country. 
http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en 
(accessed March 14, 2017).
10 Lopez AD, Salomon J, Ahmad O, Murray CJL. Life tables for 
191 countries: data, methods and results. Geneva: World Health 
Organization, 2000.
11 ICH. International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use Guideline for 
Good Clinical Practice E6(R1). June 10, 1996. https://www.ich.org/
fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
E6/E6_R1_Guideline.pdf (accessed March 3, 2017).
12 Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, 
Stoddart GL. Methods for the economic evaluation of health care 
programmes, 3rd edn. Oxford: Oxford University Press, 2005.
13 Kind P, Hardman G, Macran S. UK population norms for EQ­5D: 
discussion paper 172. York: Centre for Health Economics, 
University of York, 1999.
14 Alfirevic Z, Keeney E, Dowswell T, et al. Methods to induce labour: 
a systematic review, network meta­analysis and cost­effectiveness 
analysis. BJOG 2016; 123: 1462–70.
15 WHO. WHO­CHOICE price of local (non­traded) goods. 
http://www.who.int/choice/costs/prog_costs/en/ 
(accessed May 15, 2017).
16 WHO. WHO guideline on the use of safety­engineered syringes for 
intramuscular, intradermal and subcutaneous injections in health 
care settings. Geneva: World Health Organization, 2016.
17 WHO. WHO­CHOICE health service delivery costs. 
http://www.who.int/choice/cost­effectiveness/inputs/health_
service/en/ (accessed March 14, 2017).
18 Miners A. Estimating ‘costs’ for cost­effectiveness analysis. 
Pharmacoeconomics 2008; 26: 745–51.
19 Shemilt I, Thomas JMM. A web­based tool for adjusting costs to 
a specific target currency and price year. Evid Policy 2010; 6: 51–59.
20 Woods B, Revill P, Sculpher M, Claxton K. Country­level 
cost­effectiveness thresholds: initial estimates and the need for 
further research. Value Health 2016; 19: 929–35.
21 Bill & Melinda Gates Foundation. Methods for economic evaluation 
project (MEEP): final report. January, 2014. London: National 
Institute for Health and Care Excellence, 2014.
22 Torgerson DJ, Raftery J. Discounting. BMJ 1999; 319: 914–15.
23 Briggs AH, Claxton K, Sculpher M. Decision modelling for health 
economic evaluation. Oxford: Oxford University Press, 2006.
24 Guerriero C, Cairns J, Jayaraman S, Roberts I, Perel P, Shakur H. 
Giving tranexamic acid to reduce surgical bleeding in sub­Saharan 
Africa: an economic evaluation. Cost Eff Resour Alloc 2010; 8: 1.
25 Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. 
Cost­effectiveness analysis of administering tranexamic acid to 
bleeding trauma patients using evidence from the CRASH­2 trial. 
PLoS One 2011; 6: e18987.
26 Pinto MA, Silva JG, Chedid AD, Chedid MF. Use of tranexamic acid 
in trauma patients: an analysis of cost­effectiveness for use in 
Brazil. Arq Bras Cir Dig 2016; 29: 282–86.
27 WHO. State of inequality: reproductive, maternal, newborn and 
child health. 2015. http://www.who.int/gho/health_equity/
report_2015/en/ (accessed June 27, 2017).
28 Adeyanju O, Tubeuf S, Ensor T. Socio­economic inequalities in 
access to maternal and child healthcare in Nigeria: changes over 
time and decomposition analysis. Health Policy Plan 2017; 
32: 1111–18.
29 Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for 
the cost–effectiveness of interventions: alternative approaches. 
Bull World Health Organ 2015; 93: 118–24.
30 Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and 
improving the one and three times GDP per capita cost­effectiveness 
thresholds. Health Policy Plan 2017; 32: 141–45.
